Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-1-isopropyl-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine

Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-1-isopropyl-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine Descriptor: 5-(6-azanyl-4-methyl-1-propan-2-yl-pyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Authors: Ouvry, G, Aurelly, M, Bonnary, L, Borde, E, Bouix-Peter, C, Chantalat, L, Clary, L, Defoin-Platel, C, Deret, S, Forissier, M, Harris, C.S, Isabet, T, Lamy, L, Luzy, A.P, Pascau, J, Soulet, C, Taddei, A, Taquet, N, Tomas, L, Thoreau, E, Varvier, E, Vial, E, Hennequin, L.F. Deposit date: 2018-06-21 Release date: 2019-10-02 Last modified: 2024-05-15 Method: X-RAY DIFFRACTION (3 Å) Cite: Impact of Minor Structural Modifications on Properties of a Series of mTOR Inhibitors. Acs Med.Chem.Lett., 10, 2019

磷脂酰肌醇3-激酶α（PI3Kα）与3-(2-氨基苯并恶唑-5-基)-1-异丙基-4-甲基-1H-吡唑并[3,4-d]嘧啶-6-胺复合物的晶体结构
结构描述符：5-(6-氨基-4-甲基-1-异丙基吡唑并[3,4-d]嘧啶-3-基)-1,3-苯并恶唑-2-胺、磷脂酰肌醇4,5-二磷酸3-激酶催化亚基α亚型
作者：Ouvry, G、Aurelly, M、Bonnary, L、Borde, E、Bouix-Peter, C、Chantalat, L、Clary, L、Defoin-Platel, C、Deret, S、Forissier, M、Harris, C.S、Isabet, T、Lamy, L、Luzy, A.P、Pascau, J、Soulet, C、Taddei, A、Taquet, N、Tomas, L、Thoreau, E、Varvier, E、Vial, E、Hennequin, L.F.
存档日期：2018-06-21
发布日期：2019-10-02
最后修改日期：2024-05-15
实验方法：X射线衍射（分辨率3 Å）
引用文献：《微小结构修饰对一系列mTOR抑制剂性质的影响》，《ACS药物化学快报》，10卷，2019年